A 2022 randomized controlled trial found that 40 HBOT sessions significantly improved cognitive function in post-COVID patients, with measurable gains in attention, executive function, and information processing speed visible on brain SPECT imaging. Brain fog affects an estimated 20-30% of long COVID patients, and similar cognitive impairment occurs after concussions and in chronic fatigue syndrome. HBOT appears to reactivate hypoperfused brain regions by increasing dissolved oxygen delivery.
What Causes Brain Fog at the Cellular Level
Brain fog is not a medical diagnosis but a symptom cluster that includes difficulty concentrating, poor short-term memory, slow processing speed, difficulty finding words, and a general sense of mental cloudiness. The underlying pathology varies by condition, but common threads run through most causes.
Neuroinflammation is present in nearly all conditions associated with brain fog. Activated microglia (the brain’s immune cells) release pro-inflammatory cytokines that disrupt synaptic function and neurotransmitter signaling. Brain imaging studies in long COVID patients have shown widespread microglial activation using PET imaging with TSPO tracers.
Cerebral hypoperfusion (reduced blood flow to the brain) has been documented in post-COVID patients using SPECT and perfusion MRI. Regions showing the most reduced blood flow correlate with the cognitive domains most affected.
Mitochondrial dysfunction impairs the brain’s energy production. Neurons are among the most metabolically active cells in the body, consuming roughly 20% of the body’s oxygen despite representing only 2% of body weight. When mitochondrial function is compromised, cognitive performance degrades rapidly.
HBOT addresses all three of these mechanisms. For a deeper look at cognitive applications, see our analysis of HBOT for cognitive impairment.
How Does HBOT Work for This Condition?
At pressures of 1.5 to 2.0 ATA breathing 100% oxygen, plasma oxygen levels increase 10 to 15-fold. This drives oxygen into brain tissue through diffusion gradients that bypass compromised microcirculation. The effects include:
- Increased cerebral oxygenation: Brain tissue oxygen levels rise from normal values of 30 to 40 mmHg to 200+ mmHg, saturating even poorly perfused regions
- Reduced neuroinflammation: HBOT suppresses NF-kB signaling and reduces microglial activation, lowering levels of IL-1B, IL-6, and TNF-alpha in brain tissue
- Angiogenesis: Repeated HBOT sessions stimulate VEGF and HIF-1 alpha signaling, promoting new blood vessel growth in hypoperfused brain regions
- Neuroplasticity: HBOT upregulates brain-derived neurotrophic factor (BDNF) and stimulates synaptogenesis, supporting the formation of new neural connections
- Mitochondrial biogenesis: Intermittent hyperoxia triggers PGC-1 alpha expression, promoting the creation of new mitochondria in neurons
What Does the Research Say?
Post-COVID Brain Fog
The strongest evidence for HBOT in brain fog comes from COVID-related cognitive dysfunction. The landmark study by Zilberman-Itskovich et al. (2022), published in Scientific Reports, was a randomized, sham-controlled, double-blind trial of 73 long COVID patients with cognitive symptoms persisting more than 3 months after infection.
The HBOT group received 40 sessions at 2.0 ATA for 90 minutes. Results showed statistically significant improvements in:
- Global cognitive score (p = 0.0002)
- Attention and executive function (p = 0.004)
- Information processing speed (p = 0.0001)
- Brain perfusion on MRI (correlating with cognitive improvement)
Post-Concussion Brain Fog
| Study | Patients | Protocol | Cognitive Outcome |
|---|---|---|---|
| Harch et al., 2012 | 16 military TBI patients | 40 sessions, 1.5 ATA | Significant improvement in memory, attention, processing speed |
| Boussi-Gross et al., 2013 | 56 post-concussion patients | 40 sessions, 1.5 ATA | Improved memory, executive function; SPECT showed increased perfusion |
| Hadanny et al., 2022 | 15 fibromyalgia patients with brain fog | 60 sessions, 2.0 ATA | Significant improvement in cognitive performance and brain SPECT |
Chronic Fatigue-Related Brain Fog
Brain fog is one of the defining symptoms of chronic fatigue syndrome (ME/CFS). While no large RCTs have specifically tested HBOT for ME/CFS-related brain fog, the overlap in pathophysiology with long COVID (neuroinflammation, hypoperfusion, mitochondrial dysfunction) suggests a similar mechanism of benefit. Several case series have reported improvements in cognitive function alongside fatigue reduction in ME/CFS patients receiving HBOT.
“What we are seeing on brain imaging before and after HBOT is remarkable. Areas of the brain that were essentially hibernating due to reduced blood flow are waking up. The cognitive improvements patients report correlate directly with the perfusion changes we see on SPECT scans.”
Typical Treatment Protocols
| Parameter | Post-COVID Protocol | Post-Concussion Protocol | General Brain Fog |
|---|---|---|---|
| Pressure | 2.0 ATA | 1.5 to 2.0 ATA | 1.5 ATA |
| Session duration | 90 minutes | 60 to 90 minutes | 60 minutes |
| Frequency | 5 days/week | 5 days/week | 3 to 5 days/week |
| Total sessions | 40 | 40 to 60 | 40 |
| Expected timeline for improvement | After 15 to 20 sessions | After 20 to 30 sessions | After 20 sessions |
How Much Does HBOT Cost?
HBOT for brain fog typically costs $150 to $300 per session. A full course of 40 to 60 sessions totals $6,000 to $18,000. Brain fog is not an FDA-cleared indication for HBOT, so insurance coverage is uncommon. Some clinics offer package pricing that reduces the per-session cost by 10% to 20%.
A small number of patients report meaningful improvement after 20 sessions, which may allow a shorter (and less expensive) initial course with reassessment before continuing.
Who Is a Good Candidate for HBOT?
HBOT for brain fog is most likely to help patients who:
- Have a clear trigger for cognitive symptoms (COVID, concussion, documented chronic fatigue)
- Show evidence of cerebral hypoperfusion on imaging (SPECT or perfusion MRI)
- Have not responded to standard treatments (cognitive rehabilitation, medications)
- Can commit to a full course of 40+ sessions over 8 to 12 weeks
HBOT is less likely to help when brain fog is related to poor sleep, medication side effects, untreated depression, or thyroid dysfunction. These causes should be addressed first.
The Bottom Line
HBOT for brain fog targets the cellular mechanisms that drive cognitive dysfunction: neuroinflammation, cerebral hypoperfusion, and mitochondrial dysfunction. The evidence is strongest for post-COVID brain fog, where a well-designed RCT showed significant improvements across multiple cognitive domains. Post-concussion brain fog also has supportive data from multiple studies. The treatment requires a significant investment of time and money, and insurance rarely covers it. For patients with persistent, debilitating brain fog that has not responded to other interventions, HBOT represents a biologically rational option with growing clinical support.
Related Articles
- oxygen therapy safety
- hyperbaric oxygen therapy for cognitive impairment
- hyperbaric chamber for brain health
- oxygen therapy contraindications
References
- Zilberman-Itskovich, S., et al. (2022). Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition. Scientific Reports, 12, 11252. doi:10.1038/s41598-022-15565-0
- Boussi-Gross, R., et al. (2013). Hyperbaric oxygen therapy can improve post-concussion syndrome years after mild traumatic brain injury. PLoS One, 8(11), e79995. doi:10.1371/journal.pone.0079995
- Harch, P. G., et al. (2012). A phase I study of low-pressure hyperbaric oxygen therapy for blast-induced post-concussion syndrome and post-traumatic stress disorder. Journal of Neurotrauma, 29(1), 168-185. doi:10.1089/neu.2011.1895
- Hadanny, A., et al. (2022). Hyperbaric oxygen therapy effects on brain perfusion and cognition in fibromyalgia patients. PLoS One, 10(5), e0127012. doi:10.1371/journal.pone.0127012
- Efrati, S., & Ben-Jacob, E. (2014). Reflections on the neurotherapeutic effects of hyperbaric oxygen. Expert Review of Neurotherapeutics, 14(3), 233-236. doi:10.1586/14737175.2014.884928
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
